Numinus Wellness Inc (OTCQB:NUMIF) has been approved to use psilocybin-assisted therapy through Health Canada’s Special Access Program (SAP), marking the first instance in which Numinus will provide this treatment outside of a clinical trial.
The newly approved treatment will be done at the company’s clinic in Montreal. Patients who take part in the SAP program must have a life-threatening condition in which conventional treatments have not functioned or are not available in the country.
Professionals involved in the treatment were trained by Numinus' proprietary psilocybin-assisted therapy protocol. In addition, Numinus will partner with a Health Canada supplier, Psygen Labs, to provide the synthetic psilocybin in the dosing session.
Payton Nyquvest, CEO and founder of Numinus, said: “The SAP recognizes a growing body of research that has consistently shown the efficacy of psychedelic-assisted psychotherapy to treat a broad range of mental health conditions that are extremely difficult to treat with conventional therapies.”
Numinus' Québec regional medical director, Dr. Andrew Bui-Nguyen, added: “To our knowledge, this is the first Health Canada SAP approval for psilocybin-assisted therapy for someone suffering from treatment-resistant depression in Québec.”
